Clorox Company (The)NYSE: CLX

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

Zacks Research lowered its FY2026 earnings estimate for Clorox to $5.50 per share from $5.95, and cut FY2027 EPS to $6.00 from $6.74 in a note dated May 19, 2026. The downward revision compounds a difficult month after Clorox lowered its full-year guidance and shares fell ~9.7% following Q3 results. The company priced a $1.5 billion senior notes offering across three tranches (4.7% due 2031, 4.95% due 2033, 5.25% due 2036) to repay $1.25 billion of delayed draw term loan debt tied to the GOJO Industries acquisition. Multiple law firms including Schall Law Firm and Bronstein Gewirtz are pursuing securities fraud investigations against the company. Barclays separately lowered its CLX price target to $85 from $102 (Underweight). Hidden Valley Ranch launched a protein-forward Seasoned Chicken Dippers line in mid-May.

FY2026 Earnings Forecast for Clorox Issued By Zacks Researchdailypolitical.comCLX Investors Have Opportunity to Join The Clorox Company Fraud Investigation with the Schall Law Firmglobenewswire.comClorox in $1.5 Billion Offeringclearygottlieb.com

Clorox closed a $1.5 billion senior notes offering on May 11, 2026, comprising $550M at 4.7% due 2031, $400M at 4.95% due 2033, and $550M at 5.25% due 2036. Multiple law firms (Schall Law Firm, Bronstein Gewirtz & Grossman, Johnson Fistel) launched investor investigations following the April 30 Q3 earnings, which triggered a 9.7% drop and cut full-year adjusted EPS guidance to $4.78-$4.98 from $5.60-$5.95 due to ERP stabilization costs. Director Pierre Breber purchased 5,000 shares on May 5 (~$429K). Barclays cut its price target to $85 from $102, maintaining Underweight. Zacks Research lowered FY2026 EPS estimate to $5.50 from $5.95.

Clorox Investors Fraud Investigationglobenewswire.comClorox $1.5 Billion Offering Clearyclearygottlieb.comClorox Director Pierre Breber 5000 Sharesquiverquant.com

No material news in the last 48 hours.

Clorox completed a $1.5 billion senior notes offering that priced May 6, 2026 and closed May 11, while multiple law firms including Bronstein Gewirtz, Schall Law, Johnson Fistel, and Pomerantz launched securities fraud investigations following the company lowered FY26 guidance. Director Pierre Breber acquired 5,000 shares at $85.82 per share on May 5 totaling roughly $429,124. The company cut full-year adjusted EPS guidance to $4.78-$4.98 from $5.60-$5.95 and lowered gross margin outlook to decline 250-300 basis points, with shares falling 9.67% to $87.11 on May 1 after the disclosure. Goldman Sachs lowered its price target to $83 and Morgan Stanley cut to $97 in early May. The company remains on track to become a Dividend King in 2027 with its 50th consecutive year of dividend increases.

Clorox in $1.5 Billion Offeringclearygottlieb.comCLX Investors Have Opportunity to Join Clorox Fraud Investigationglobenewswire.comCLX Director Breber Buys 5,000 Shares on May 06, 2026meyka.com

Clorox raised $1.5 billion through a senior notes offering on May 11, 2026. The company is facing a securities fraud investigation and lowered its full-year outlook. Q3 FY2026 EPS of $1.64 beat estimates by 5.81% on revenue of $1.67B that met forecasts. However, gross margin fell short due to elevated supply chain costs from ERP implementation challenges. Full-year gross margin guidance was revised downward to a decline of 250-300 basis points versus prior 100 bps forecast. The lowered outlook led to a 9% drop in shares, pushing the stock to an 11-year low. Analyst PT cuts: Goldman Sachs $94 to $83, Morgan Stanley $110 to $97. Stock at $90.13.

Clorox sees more work ahead, lowers FY26 outlook - Seeking Alphaseekingalpha.comClorox Stock Price - Investing.cominvesting.comClorox (CLX) Stock News - MarketBeatmarketbeat.com

Multiple law firms including Schall Law Firm, Bronstein Gewirtz & Grossman, and Johnson Fistel announced investigations of The Clorox Company on May 11-13, 2026 for potential securities law violations. The investigations follow Q3 2026 results on April 30 that revealed decreased gross margin, a lowered full-year gross margin outlook, and a 9.4% reduction in full-year adjusted EPS guidance — sending shares down more than 9.6% on May 1. On May 6, Clorox executed an underwriting agreement to issue $1.5B in senior notes across 2031, 2033, and 2036 tranches. Goldman Sachs lowered its price target to $83 from $94 with a Sell rating. Hidden Valley Ranch launched new Dippers protein snacks on May 11 at major retailers. ERP implementation is complete and the GOJO acquisition is expected to be accretive despite near-term margin dilution. Major legal and operational risk overhang.

CLX Investors Have Opportunity to Join Fraud Investigationglobenewswire.comClorox Raises $1.5 Billion Through Senior Notes Offeringtipranks.comHidden Valley Ranch Expands into Protein Snackinginvestors.thecloroxcompany.com

On May 11, 2026, the Schall Law Firm announced it is investigating The Clorox Company for potential securities fraud violations, joining several other firms (Johnson Fistel, Bronstein Gewirtz & Grossman, Pomerantz) that have opened investigations into the same disclosures. The probes stem from Clorox's May 1 Q3 fiscal 2026 earnings release, which sent shares down 9.67% to $87.11 after the company cut its full-year gross margin outlook to a 250-300 bps decline (versus prior 50-100 bps) and cited ERP stabilization issues and higher supply chain costs. Goldman Sachs cut its price target to $83 (from $94) maintaining Sell, while Barclays cut to $85 (from $102) with Underweight. Director Pierre Breber bought 5,000 shares on May 6 for about $429,124, providing a partial offset. The company also raised $1.5 billion through senior notes on May 9 and launched a new Hidden Valley Ranch ready-to-eat chicken product on May 11. Litigation overhang and gross margin pressure remain the key risks.

CLX Investors Have Opportunity to Join The Clorox Company Fraud Investigation with the Schall Law Firmglobenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Clorox Companyprnewswire.comThe Clorox Company (CLX) Latest Stock News & Headlinesfinance.yahoo.com

Schall Law Firm publicly invited CLX investors to join a fraud investigation on May 11, the latest in a string of law-firm probes (Bronstein/Gewirtz, Johnson Fistel) following Clorox's April 30 Q3 fiscal 2026 report. Clorox lowered FY26 EPS guidance to $4.78-$4.98 from $5.60-$5.95 and now expects gross margin to decline 250-300bps (versus prior 50-100bps) due to ERP-stabilization costs. Goldman cut its target to $83 (Sell) and Barclays to $85 (Underweight). Director Pierre Breber bought 5,000 shares at $85.82 on May 6 (~$429K). Bear case: securities-fraud probes plus a slashed outlook have erased ~30% of the share price.

CLX Investors Have Opportunity to Join Clorox Fraud Investigationglobenewswire.comInsider Purchase: Director at $CLX Buys 5,000 Sharesquiverquant.com

Clorox reported Q3 FY2026 results on April 30, 2026 with gross margin down 140 bps to 43.2% due to higher supply chain costs and delayed cost savings tied to ERP stabilization. The company cut FY2026 EPS guidance to $4.78-$4.98 from $5.60-$5.95 and now expects gross margin to decline 250-300 bps vs prior 50-100 bps. The stock dropped 9.67% to $87.11 on May 1 and has fallen ~33% over the past year. Several law firms launched securities fraud investigations into the GOJO acquisition integration issues. Director Pierre Breber purchased 5,000 shares on May 6 for ~$429,124, signaling insider confidence. The dividend yield reached a multi-decade high of 5.7%.

Clorox high-yield dividend stock - Motley Foolfool.comClorox shareholders Johnson Fistelglobenewswire.comCLX Director Breber Buys 5,000 Sharesmeyka.com